Back
41
8
Day Range
$19.74
$19.74
52-Week Range
—
Volume
900
50D / 200D Avg
—
/
—
Prev Close
$19.74
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 0.1 | 0.4 |
| P/B | 0.0 | 2.9 |
| ROE % | 6.7 | 3.7 |
| Net Margin % | 8.4 | 3.9 |
| Rev Growth 5Y % | 5.6 | 10.0 |
| D/E | 0.1 | 0.2 |
Analyst Price Target
No analyst coverage available
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2028 |
$203.99
$203.99 – $203.99
|
130 B | 1 |
| FY2027 |
$191.54
$191.54 – $191.54
|
120 B | 1 |
| FY2026 |
$180.80
$180.80 – $180.80
|
110 B | 1 |
Key Takeaways
Revenue grew 5.64% annually over 5 years — modest growth
Earnings declined -14.49% over the past year
Debt/Equity of 0.05 — conservative balance sheet
Generating 5.99B in free cash flow
P/E of 0.13 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 3.22%
Growth
Revenue Growth (5Y)
5.64%
Revenue (1Y)2.42%
Earnings (1Y)-14.49%
FCF Growth (3Y)1099.64%
Quality
Return on Equity
6.65%
ROIC6.75%
Net Margin8.37%
Op. Margin11.95%
Safety
Debt / Equity
0.05
Current Ratio3.67
Interest Coverage78.65
Valuation
P/E Ratio
0.13
P/B Ratio0.01
EV/EBITDA-2.08
Dividend Yield0.03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 2.42% | Revenue Growth (3Y) | 4.72% |
| Earnings Growth (1Y) | -14.49% | Earnings Growth (3Y) | -0.72% |
| Revenue Growth (5Y) | 5.64% | Earnings Growth (5Y) | 1.34% |
| Profitability | |||
| Revenue (TTM) | 108.58B | Net Income (TTM) | 9.08B |
| ROE | 6.65% | ROA | 4.96% |
| Gross Margin | 48.40% | Operating Margin | 11.95% |
| Net Margin | 8.37% | Free Cash Flow (TTM) | 5.99B |
| ROIC | 6.75% | FCF Growth (3Y) | 1099.64% |
| Safety | |||
| Debt / Equity | 0.05 | Current Ratio | 3.67 |
| Interest Coverage | 78.65 | Dividend Yield | 0.03% |
| Valuation | |||
| P/E Ratio | 0.13 | P/B Ratio | 0.01 |
| P/S Ratio | 0.01 | PEG Ratio | -1.45 |
| EV/EBITDA | -2.08 | Dividend Yield | 0.03% |
| Market Cap | 1.15B | Enterprise Value | -26.99B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 108.58B | 106.02B | 99.01B | 90.35B | 87.17B |
| Net Income | 9.08B | 10.62B | 9.22B | 9.09B | 8.61B |
| EPS (Diluted) | 159.24 | 182.61 | 158.37 | 156.39 | 148.15 |
| Gross Profit | 52.56B | 50.63B | 355.30M | 353.51M | 365.95M |
| Operating Income | 12.98B | 13.82B | 13.45B | 12.34B | 11.58B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 183.03B | 180.02B | 1.30B | 1.35B | 1.40B |
| Total Liabilities | 45.74B | 44.01B | 328.13M | 349.99M | 366.81M |
| Shareholders' Equity | 137.28B | 136.01B | 128.70B | 121.67B | 113.82B |
| Total Debt | 6.81B | 5.96B | 5.51B | 6.14B | 7.13B |
| Cash & Equivalents | 34.94B | 33.83B | 343.71M | 373.47M | 368.82M |
| Current Assets | 94.53B | 95.50B | 97.14B | 94.04B | 86.14B |
| Current Liabilities | 25.76B | 24.90B | 26.30B | 25.39B | 23.72B |
Strategy Scores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#428 of 820
#590 of 708
Recent Activity
Entered
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered
Defensive Investing (Benjamin Graham)
Mar 24, 2026